Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization

Mohammad Ali Sadiq, Mostafa Hanout, Salman Sarwar, Muhammad Hassan, Diana V. Do, Quan Dong Nguyen, Yasir Jamal Sepah

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy (DR), retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factor (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF plays an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly AMD, has become more exciting due to agents such as PDGF antagonists.

Original languageEnglish (US)
Pages (from-to)287-291
Number of pages5
JournalSaudi Journal of Ophthalmology
Volume29
Issue number4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Growth Inhibitors
Platelet-Derived Growth Factor
Vascular Diseases
Macular Degeneration
Degenerative Myopia
Retinal Vein Occlusion
Retinopathy of Prematurity
Diabetic Retinopathy
Blindness
Therapeutics

Keywords

  • Age related macular degeneration
  • Diabetic retinopathy
  • PDGF
  • Platelet derived growth factor
  • Retinal vascular disease

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Sadiq, M. A., Hanout, M., Sarwar, S., Hassan, M., Do, D. V., Nguyen, Q. D., & Sepah, Y. J. (2015). Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization. Saudi Journal of Ophthalmology, 29(4), 287-291. https://doi.org/10.1016/j.sjopt.2015.05.005

Platelet derived growth factor inhibitors : A potential therapeutic approach for ocular neovascularization. / Sadiq, Mohammad Ali; Hanout, Mostafa; Sarwar, Salman; Hassan, Muhammad; Do, Diana V.; Nguyen, Quan Dong; Sepah, Yasir Jamal.

In: Saudi Journal of Ophthalmology, Vol. 29, No. 4, 01.01.2015, p. 287-291.

Research output: Contribution to journalReview article

Sadiq, Mohammad Ali ; Hanout, Mostafa ; Sarwar, Salman ; Hassan, Muhammad ; Do, Diana V. ; Nguyen, Quan Dong ; Sepah, Yasir Jamal. / Platelet derived growth factor inhibitors : A potential therapeutic approach for ocular neovascularization. In: Saudi Journal of Ophthalmology. 2015 ; Vol. 29, No. 4. pp. 287-291.
@article{be92415e3b6343f5af8898b0780afd4d,
title = "Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization",
abstract = "Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy (DR), retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factor (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF plays an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly AMD, has become more exciting due to agents such as PDGF antagonists.",
keywords = "Age related macular degeneration, Diabetic retinopathy, PDGF, Platelet derived growth factor, Retinal vascular disease",
author = "Sadiq, {Mohammad Ali} and Mostafa Hanout and Salman Sarwar and Muhammad Hassan and Do, {Diana V.} and Nguyen, {Quan Dong} and Sepah, {Yasir Jamal}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.sjopt.2015.05.005",
language = "English (US)",
volume = "29",
pages = "287--291",
journal = "Saudi Journal of Ophthalmology",
issn = "1319-4534",
publisher = "King Saud University",
number = "4",

}

TY - JOUR

T1 - Platelet derived growth factor inhibitors

T2 - A potential therapeutic approach for ocular neovascularization

AU - Sadiq, Mohammad Ali

AU - Hanout, Mostafa

AU - Sarwar, Salman

AU - Hassan, Muhammad

AU - Do, Diana V.

AU - Nguyen, Quan Dong

AU - Sepah, Yasir Jamal

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy (DR), retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factor (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF plays an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly AMD, has become more exciting due to agents such as PDGF antagonists.

AB - Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy (DR), retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factor (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF plays an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly AMD, has become more exciting due to agents such as PDGF antagonists.

KW - Age related macular degeneration

KW - Diabetic retinopathy

KW - PDGF

KW - Platelet derived growth factor

KW - Retinal vascular disease

UR - http://www.scopus.com/inward/record.url?scp=84952873484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952873484&partnerID=8YFLogxK

U2 - 10.1016/j.sjopt.2015.05.005

DO - 10.1016/j.sjopt.2015.05.005

M3 - Review article

C2 - 26586980

AN - SCOPUS:84952873484

VL - 29

SP - 287

EP - 291

JO - Saudi Journal of Ophthalmology

JF - Saudi Journal of Ophthalmology

SN - 1319-4534

IS - 4

ER -